References
1. Leung, N. et al. Monoclonal gammopathy of renal significance:
when MGUS is no longer undetermined or insignificant. Blood120 , 4292–4295 (2012).
2. Steiner, N. et al. Monoclonal gammopathy of renal significance
(MGRS) increases the risk for progression to multiple myeloma: an
observational study of 2935 MGUS patients. Oncotarget 9 ,
2344–2356 (2018).
3. Dimopoulos, M. A. et al. Primary therapy of Waldenström
macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone,
and rituximab (BDR): Long-term results of a phase 2 study of the
European Myeloma Network (EMN). Blood 122 , 3276–3282
(2013).
4. Bridoux, F. et al. Diagnosis of monoclonal gammopathy of renal
significance. Kidney Int. 87 , 698–711 (2015).
5. Fermand, J.-P. et al. How I treat monoclonal gammopathy of
renal significance (MGRS). Blood 122 , 3583–90 (2013).
6. Nasr, S. H. et al. Immunotactoid glomerulopathy:
clinicopathologic and proteomic study. Nephrol. Dial. Transplant27 , 4137–46 (2012).
7. Heilman, R. L., Velosa, J. A., Holley, K. E., Offord, K. P. & Kyle,
R. A. Long-term follow-up and response to chemotherapy in patients with
light-chain deposition disease. Am. J. Kidney Dis. 20 ,
34–41 (1992).
8. Sethi, S. & Rajkumar, S. V. Monoclonal Gammopathy–Associated
Proliferative Glomerulonephritis. Mayo Clin. Proc. 88 ,
1284–1293 (2013).
9. Gumber, R. et al. A clone-directed approach may improve
diagnosis and treatment of proliferative glomerulonephritis with
monoclonal immunoglobulin deposits. Kidney Int. 94 ,
199–205 (2018).